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Abstract The current developments in metabolomics and
metabolic profiling technologies have led to the discovery
of several new metabolic biomarkers. Finding metabolites
present in significantly different levels between sample sets,
however, does not necessarily make these metabolites
useful biomarkers. The route to valid and applicable
biomarkers (biomarker qualification) is long and demands
a significant amount of work. In this overview, we critically
discuss the current state-of-the-art of metabolic biomarker
discovery, with highlights and shortcomings, and suggest a
pathway to clinical usefulness.
Keywords Biomarkerdiscovery.Biomarkervalidation.
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Introduction
Biomarker discovery has traditionally played an important
role in medicine, dating back to medieval times when urine
was used to diagnose the health of people based on markers
such as colour, smell and taste. Similar to drug discovery,
methods and applications of biomarkers have slowly
evolved. The discovery and qualification of new bio-
markers has usually been the domain of clinical chemists,
with a range of metabolic biomarkers being routinely
measured today. More recently genomics and proteomics
have promised biomarkers for improving the diagnosis and
prognosis of pathologies [1].
The apparent usefulness of new biomarkers has made
biomarker discovery a tangible aim in the life sciences.
Metabolomics and metabolic profiling have recently be-
come very popular in many research projects and often
promise discovery of useful novel biomarkers. The majority
of these projects, aided by advanced bioinformatics
techniques, reveal one or more metabolites at differential
levels between sample sets believed to be indicative of a
disease, a physiological condition or a similar health-related
target. Currently, many research reports and publications
designate such metabolites as biomarkers. Most of these
studies, however, take the research no further than the
discovery stage. Very rarely are these new “biomarkers”
validated, leading to an untimely and sometimes unde-
served “death” of the biomarker. This lack of validation and
translation (called “biomarker qualification” by the US
Food and Drug Administration [2, 3]) is undoubtedly
detrimental to the metabolomics science. Indeed, this is
exactly where the major scientific challenges now are, and
lack of progress may ultimately lead to loss of interest of
funding agencies and industry in metabolic biomarkers.
This “black cloud” is not only hanging over metabolo-
mics; proteomics has long been promising new biomarkers,
but has so far failed to deliver anything clinically applicable
[4]. As metabolomics is the newcomer, it should learn from
the “mistakes” and shortcomings of proteomics. Impor-
tantly, it must be understood that there are significant
differences between metabolomics and proteomics. Still,
there is little doubt that metabolic biomarkers will follow,
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The aim of this short perspective is to critically discuss
the current state-of-the-art of metabolic biomarker discov-
ery, with highlights and shortcomings, and to suggest a
pathway to clinical usefulness.
Cynics will argue that discovering differentiating metab-
olites is the same as spotting the differences between two
cartoons commonly found in puzzle books. The main
difference is that the data-mining tools involved make this
a somewhat more sophisticated and expensive exercise, with
the cartoons being generated by multimillion-dollar instru-
ments. Noticing differences between the metabolic profiles
in urine samples of a severe diabetic and a healthy mouse is
still roughly the same exercise; and it is not much more
scientifically interesting or useful. In reality the discovery of
differentiating metabolites between sample sets is as far from
establishing a qualified and useful biomarker as is finding a
compound that is active in an in vitro bioassay from this
compound becoming the basis of a new drug.
Humans or animals showing clear, easy to diagnose
pathophysiological changes are usually very sick creatures
suffering from derailed homeostasis; a complex set of
problems that may be secondary or tertiary effects of the
original cause. Most of these processes are disease side
effects or processes, where the metabolism is trying to
compensate for the perturbation of the underlying respon-
sible illness. Metabolic differences between healthy and
sick individuals can be significant but are likely to relate to
the consequences rather than the causes of the pathology,
and be biologically or medically of little predictive
relevance. More importantly, the measurement of these
differences by “comprehensive” metabolomics methods
will probably lack the precision and accuracy that is needed
in a clinical setting. In almost all cases, differentiating
metabolites can only become diagnostic biomarkers after a
multistep qualification process, rigorously testing precision,
accuracy and diagnostic/prognostic value.
The ideal design of an experiment for biomarker
discovery incorporates one or more steps towards qualifi-
cation. At the very least, it should clearly foresee the next
required steps. At the same time, editors and referees of
scientific journals as well as funding agencies should feel
obliged to scrutinize these projects, to make sure that
biomarkers can and will go through qualification steps.
In light of this situation, we suggest a different
terminology for the biomarker discovery, qualification and
application stages (Fig. 1). During the first stage, differen-
tiating metabolites are obtained, in particular for two-way
comparisons (sick versus healthy, before and after dosage
etc.). More sophisticated projects will use multiple sam-
pling points (over different time points or from different
tissues) or a range of stages of disease, concentrations of
dosage etc. In such cases, it may be better to call the
discovered compounds indicating metabolites;i nt h i s
article, we will continue to use the more general phrase
differentiating metabolite though. After the differentiating
or indicating metabolites are unambiguously identified, the
biological relevance to the underlying pathology should
become apparent. We suggest that only after sufficient
proof of the precision and accuracy, possible chemical and
biological interferences etc., there is sufficient proof for a
differentiating metabolite to be moved to the status of
candidate biomarker. When the candidate biomarkers are
subsequently tested and clearly show established utility,
they reach the application stage. In our opinion, they can
only genuinely be called biomarkers at that stage (Fig 1).
Differentiating metabolites
The quality of the initial sample set determines the
specificity, accuracy and application range of discovered
metabolites and determines the chance of successful
translation to clinical applications. It is therefore best to
use the term differentiating metabolites at this stage, as
there is no proof that differentiating metabolites from the
initial study will show the same treatment differences in
subsequent experiments. The fact that a number of metabo-
lites show a differentiating behaviour may simply be the
result of the profiling or sampling method used, or
particular circumstances of the experiment rather than a
real biological phenomenon. Many biomarker discovery
projects focus on health versus disease. Diseases will often
Fig. 1 The process of biomark-
er discovery covers more than
finding differentiating
metabolites
664 A. Koulman et al.result in general perturbations of homeostasis, with many
general metabolic pathways affected. Although this can lead
to significant changes of some metabolites, it may not be
specific to the disease or pathology, resulting only in a marker
for general illness rather than a marker for a specific disease.
Experimental design
The experimental design offers two possible strategies, neither
of which is error-proof. A highly controlled experiment can be
designed, differing only in the single parameter of interest.
This will yield a highly specific differentiating metabolite, but
mayshowvery littlerobustness;or in otherwords, it may only
be valid under the particular circumstances of the experiment.
When that experimental control is relaxed, the accuracy and
precisionofthedifferentiatingmetabolitesbecomelesscertain.
It will be much more difficult to guaranty that other factors are
evenly and randomly distributed across the samples, introduc-
ing the possibility that metabolic differentiation derives from
unknown biases present in the sample set. This will demand
larger sample numbers, to gain enough statistical power to
determine relevant differentiating metabolites. In the end, it is
less important which experimental design is followed as long
as the scientists involved are aware of the possible short-
comings and develop their qualification accordingly.
Biological or analytical differences
Most biomarker discovery projects use unbiased metabolic
profiling methods, allowing rapid analysis of large sample
sets for multivariate statistics with a sufficient base.
Scientists often design highly controlled experiments based
on 50 to 100 samples (Table 1). The methods can easily
yield over 1,000 variables. Analysing such a large number
of analytes in a short analysis time can compromise the
precision and accuracy, as compared to traditional targeted
analysis. In these statistically underpowered experiments,
there will be a high rate of false positive discoveries
without very stringent significance thresholds. Importantly,
it is impractical to validate an analytical method before
knowing which metabolite is of interest as a biomarker. The
first and possibly most essential step towards validating
differentiating metabolites is therefore reanalysis of a subset
of the samples by using a different method targeted
specifically towards the differentiating metabolites, to
confirm the initial findings and reduce the possibility of
analytical bias of the first method in the discovery phase.
This is by far the easiest step in the qualification process
and, importantly, does not require new biological experi-
ments. It does, however, leave a chance of unwanted biases
in the sample set. It is advisable to re-extract the samples.
This procedure is standard practice in other fields of
analytical sciences, to assess the accuracy of any new
analytical method. Unfortunately, scientists often seem
overly confident in their methodologies and results are
often presented without this step. Even the most carefully
performed, targeted GC-MS analysis, using isotopically
labelled internal standards for the analysed metabolites can
result in CVs of 30% [6] and a less targeted approach will
almost certainly introduce a high chance of machine bias in
metabolomic analyses. For scientific publications, journal
editors and referees should not accept manuscripts present-
ing the discovery of differentiating metabolites without a
proper qualification using complementary analytical meth-
ods. Even for NMR profiling, the use of an alternative
analysis to prove both the identity and the quantification
should be mandatory, unless differentiating metabolites can
be identified and quantified with multiple signals.
Unambiguous identification
The identification of metabolites remains a major bottleneck
for metabolomics. A significant part of the human metab-
olome remains unidentified. These unknowns might be
genuinely unreported or they may not yet be known from
human samples. This lack of knowledge seriously hampers
the rapid assimilation of metabolomics data in systems
biology approaches and obstructs many biomarker projects.
The first challenge isrecognitionofknowncomponentsofthe
metabolome. Current initiatives to describe the human
metabolome either based on literature (e.g. Human Metab-
olome Database (HMDB)
1 [7]) or chemical data (MassBank
2
[8], Metlin
3 [9]) are extremely helpful and enable rapid
dereplication of identification endeavours. International
collaborations to consolidate these databases to create one
comprehensive standardized database are highly desirable.
Such a standard database would encourage submission of
data from those who currently are unsure about the choice of
database. One universal database would not only improve
the dereplication process but also assist in the interpretation
of metabolomics results and help in understanding the
biological relevance of differentiating metabolites. Journals
publishing metabolomics data should strive to include the
data on structural characterisation in detail, so that this
information reaches the public domain. The submission of
data should discriminate between unambiguously identified
novel metabolites and unknowns or partially identified
compounds, but give a similar level of detail in both cases,
which could help in identification by other groups.
1 http://www.hmdb.ca
2 http://www.massbank.jp
3 http://metlin.scripps.edu
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666 A. Koulman et al.The process of unambiguous identification is tedious.
Many scientific papers suffice with reporting accurate
masses and retention times to “identify” metabolites
(Table 1). In many studies, the metabolites are annotated
as unknown. Where putative identifications are made,
repeat analyses, including standards to verify the identi-
fications, are often omitted.
It almost appears as if the significant amount of effort
required to unambiguously identify a metabolite has made
it acceptable to simply report differentiating metabolites as
unknowns. This should be discouraged, as the usefulness of
unidentified metabolites is very limited. In contrast to
genomics and proteomics, where pieces of DNA or
unknown peptides can at least be sequenced, it is
impossible to link unknowns from a metabolomics study
to those of other studies, or to metabolic pathways and
metabolites within the current study. Furthermore, chemical
identification is important for devising new efficient
measurement techniques for later stages of qualification,
which may be different from the initial discovery.
The subsequent fate of published unknowns is obscure.
There are several scientific and practical problems with
publishing unknowns. First, it is usually not clear to what
extent the authors have tried to identify the unknowns; i.e. an
unknown in one paper may be reported as an identified
compound in another paper. The second problem is that
spectral or chromatographic data are not always adequate or
reliable. For example, Table 2 lists a few m/z ratios and
retention times from published metabolomics studies. Yin et
al. describe a phosphatidylcholine moiety at m/z 184.422
[10]. This number may be precise but it is not very accurate,
as the calculated exact mass is 184.1507. The lack of
accuracy is difficult to determine and makes database
searching impossible. Furthermore, Table 2 gives three
different reports for an unknown at m/z 235. All three
studies, however, have determined these ratios to a different
number of significant figures. It remains unclear whether
these three compounds are the same or whether they are
three different unknown compounds. Sun et al. propose a
molecular formula, but fail to report that an aromatic
heterocyclic compound of C8H11N8O is probably not from
human origin, weakening their assumption. There is current-
ly no established path to relating unknowns from different
studies, but listing retention time and m/z only clearly is not
sufficient. The definition of the minimal amount of informa-
tion needed to identify unknowns across different studies has
been the subject of considerable discussion, and an expert
group has suggested that a combination of MS/MS spectrum,
accurate mass and retention time relative to a standard might
be sufficient [11]. These criteria have not been consistently
tested yet and more evaluation is required. In the interim,
authors, referees and journal editors should apply these
minimal criteria.
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From differentiating metabolites to biomarkers 667The first step in identification is usually classification.
Some classes of metabolites are less useful as biomarkers
than others, e.g. phospholipids (vide infra), which may be
sufficient to decide on further identification. Unambiguous
identification of target metabolites means that chromato-
graphic properties and spectral data of differentiating
metabolite are identical to those of authentic standards
analysed in the same laboratory. A less rigorous identifica-
tion can be based on close similarity to published data. If
identifying data for the metabolite is not available from the
literature or databases, isolation of the compound followed
by multidimensional NMR, x-ray analysis or total synthesis
are currently the only practical options to fully elucidate the
structure of the metabolite. Obviously, this requires a
significant amount of work, especially when the metabolite
is present at very low levels (micromolar or less) or only
limited tissue amounts are available for isolation. If this
identification procedure is impossible, authors should be
very reluctant to emphasise their discovery, but more
importantly, journal editors should scrutinise the reproduc-
ibility and usefulness of the data.
Biomarkers and biology
The unambiguousidentificationofa differentiatingbiomarker
is important from a biological point of view. For example,
phospholipids (phosphotidylcholines) and ceramides might
differ between sample groups but what does that really mean?
In five of the studies listed in Table 1, glycerophosphatidyl-
cholines (C16:0 and C18:2) are reported as differentiating
metabolites. However, all five studies cover different
pathologies in different organisms: chronic acute deteriora-
tion of liver function [12] to intestinal fistula [10], obese rats
[13], viral infections of rhesus macaques [14] and abnormal
savda (traditional Uighur medicine diagnosis [15]). Wikoff et
al. [14] confirmed the upregulation of phospholipid biosyn-
thesis by additional experiments focusing on regulation of
phospholipase A2 isoenzyme. In a further unrelated study on
prostate cancer in mice, phospholipid metabolism was also
shown as changing, measured by NMR [16]. These six
totally unrelated studies imply that several major phospho-
lipids are the first class of compounds to change when the
homeostasis of a biological system is perturbed, clearly
showing that scientists must be very careful when assigning
phospholipids as specific biomarkers. A careful scrutiny on
the biochemistry of differentiating metabolites is an essential
part of the biomarker discovery process. The purpose of
understanding the biology is not only an interesting exercise;
it is vital to the next step in biomarker discovery, as it is the
best source of information on the likely relevance, specificity
and robustness. A biomarker must not merely show a
difference between healthy controls and individuals with a
certain pathophysiology; it must be a distinctive difference.
That is, conceptually the control group is not just a group of
healthy individuals, but also a group of subjects with all
other pathophysiologies. The extensive body of physiolog-
ical literature may provide indications whether other patho-
physiological processes as well as normal biological
fluctuations of that particular metabolite affect the level of
a particular differentiating metabolite, and metabolomics
databases such as HMDB can play an important role here.
Although the abovementioned example seems to paint a
somewhat grim picture of metabolomics-based biomarker
Table 2 Various markers observed in different studies showing difficulty of comparing retention times (Rt) and m/z of unknowns
Rt (min) m/z Annotation Calculated accurate
mass (m/z)
Method Reference
15.05 184.2 Phosphatidylcholine moiety 184.1507 LC-MS [10]
17.365 184.422 Phosphatidylcholine moiety 184.1507 UPLC-QTOF-MS [8]
6.4 235.1044 UN (C8H11N8O) 235.1056 UPLC-QTOF-MS [25]
7.78 235.2 UN NA LC-MS [10]
2.3 235.4 UN NA UPLC-QTOF-MS [18]
7.393 496.3396 1-Palmitoyllysophosphatidylcholine (C24H50NO7P) 496.3398 UPLC-QTOF-MS [11]
7.677 522.3551 1-Oleoylglycerosphosphocholine (C26H52NO7P) 522.3554 UPLC-QTOF-MS [11]
8.750 524.3715 1-Stearoylglycerosphosphocholine (C26H54NO7P) 524.3711 UPLC-QTOF-MS [11]
6.940 520.3401 1-Linoleoylglycerosphosphocholine (C26H54NO7P) 520.3398 UPLC-QTOF-MS [11]
38.6 496.3373 LPC (16:0) (C24H50NO7P) 496.3398 LC-TOF [12]
39.5 522.3542 LPC (18:2) (C26H52NO7P) 522.3554 LC-TOF [12]
43.5 524.3720 LPC (18:0) (C26H54NO) 524.3711 LC-TOF [12]
LC-TOF liquid chromatography–time-of-flight, LC-MS liquid chromatography–mass spectrometry, QTOF-MS quadrupole time-of-flight mass
spectrometry, UPLC-MS ultra-performance liquid chromatography–mass spectrometry, NA not applicable, UN unknown
668 A. Koulman et al.discovery, there are several studies that do find new
metabolites showing clear biological relations to the under-
lying pathology [17], and that have been moved towards the
qualification process [18, 32].
Finishing stage 1
At thispoint of the research, itbecomes necessary tocarry out
initial qualification studies to decide whether it is worth
advancing a differentiating metabolite to the status of a
candidate biomarker. Based on identity, literature data and the
first initial qualification study, it should clear if the differen-
tiating metabolite is worth pursuing. A first step towards
initial qualification will be the development of a fast and
inexpensive methodforbiomarker detection.Thismethodhas
to be precise, accurate and compatible with very large sample
sets. The method also needs to be carefully validated and
readily transferred to a routine environment. This new fully
validated method can then be applied to a completely new
sample set, preferably from an experiment specially designed
for this purpose. It can be of similar size or even smaller than
the original experiment. In this study, fewer variables are
being monitored (i.e. only the already identified differentiat-
ing metabolites), thus the statistical power of the experiment
will be higher. Preferably, the experiment will cover a wider
population and a wider set of sampling conditions. The
purpose of this experiment is to confirm the differential
behaviour of the metabolite(s) and exclude any chances that
the differential behaviour is originating from unwanted or
unexpected biases in the initial sampling (Fig. 2). A positive
result in this experiment successfully closes stage 1 of the
qualification and promotes the differentiating metabolite to a
candidate biomarker.
Stage 2: Now the hard work begins…
All the preceding work was focused on the question:
Are there any metabolites that differ in concentration
levels between samples from the test population indicative
of a specific pathophysiology?
At the end of stage 1, there should be a validated
positive answer to this question.
In stage 2, the same question will be pursued from a
different angle:
Does an abnormal level of this specific metabolite
clearly indicate a specific pathophysiology when the other
symptoms are considered?
Although the two questions are very similar, the required
work for answering the latter question is much more
complicated, because to show that a biomarker is specific,
it becomes necessary to exclude all other possibilities of
false positive or false negative results. It is necessary to
generate a sample set significantly more elaborate than the
previous experiments, reflecting the expected population to
which the biomarker will be applied. The sample set should
cover a large range of time points and large range of
severities of the pathophysiology of interest. Care should be
taken that factors such as diet, sampling time etc. are not
introducing similar biases to those that may have driven
metabolic differentiation in the discovery phase. The results
will again be the basis for a decision on the efficacy of the
candidate biomarker. Using a much larger sample set in
combination with a validated measurement will reveal the
detailed behaviour of the candidate biomarker with respect
to viability in a clinical application. The factors chosen at
this stage can significantly affect the applicability of any
biomarker-based diagnostic test and should be clearly stated
in any report. Subsequently, it is necessary to test the
behaviour of the candidate biomarker extensively in healthy
individuals, which will show the likelihood of false
positives. While database and literature investigations
should already have excluded generic biomarkers of ill
health (vide supra), it is now necessary to analyse samples
from patients with related pathophysiologies, to determine
the specificity of the biomarker. At this stage, a full
understanding of the behaviour of the candidate biomarker
under a wide range of circumstances should be reached.
That is, analysis of the biomarker in one sample should
give a clear diagnosis, with a known probability for both
false positive and negative results. It would also be highly
desirable to have additional scientific evidence on the
mechanisms underlying the relation between candidate
biomarker and pathophysiology of interest.
The final stage of the qualification process is a test
phase, where biomarker analysis is used routinely next to
conventional methods. When the biomarker shows clear
advantages over the conventional methodology (and is
Fig. 2 The design of biomarker discovery experiments determines
specificity and robustness of biomarkers; more controlled experiments
are more specific, but decrease the robustness; less controlled
experiments will give more robust biomarkers, but may introduce
unexpected biases
From differentiating metabolites to biomarkers 669economically viable), the candidate biomarker can be
moved to the stage of a genuine biomarker. This last stage
is well removed from the initial discovery phase in terms of
processes and time, and publication of interim findings can
be warranted. At the current stage of development of
metabolomics, innovative research directed at the early
stages of the pathway to qualified biomarkers is of wide
interest and worth putting on public record. However, it
would be very desirable to see the focus of research efforts
and publications move from the detection of differentiating
metabolites to the process of progressing these initial leads
to candidate and qualified biomarkers. Progress in bio-
marker development will also be advanced if characterising
data for the identification of metabolites and evidence for
the perturbation of metabolites under different pathophysi-
ologies are not only published but also logged in readily
accessible public databases such as HMDB.
Outlook to the future of biomarker-based diagnostics
Metabolomics is still in its infancy and has made great
strides to prove its efficacy in the medical field. A number
of reported metabolomic experiments have clearly shown
its usefulness in finding diagnostic aids for the medical
profession [17, 18, 25, 32]. It is also clear, however, that for
metabolomics to advance in this field, a greater degree of
scientific rigour will be needed in the future. This will
occur either through self-regulation or through legislation,
probably through both. We hope that metabolomics
scientists will be at the forefront of this debate rather than
trailing it. With the advent of more sensitive and advanced
instrumentation and the data handling tools to cope with the
large datasets, metabolomics is expected to grow signifi-
cantly in importance, as long as the practitioners remember
to apply good scientific practice in their experiments.
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